Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Timothy R Sterling a Johns Hopkins University Center for Tuberculosis
Research, 424 N Bond Street, Baltimore, MD 21231, USA, b Department of Health Sciences Information, Johns
Hopkins University School of Medicine, 2024 E Monument Street,
Baltimore, MD 21287-0007, c New York City Department
of Health, 125 Worth Street, New York, NY 10013, USA
Correspondence to: T R Sterling
Objective:
This study sought to determine the impact of the World Health Organization's directly observed treatment strategy (DOTS) compared with that of DOTS-plus on tuberculosis deaths,
mainly in the developing world.
What is already known on this topic
DOTS may be insufficiently effective in treating multidrug resistant
tuberculosis The use of toxic reserve drugs (DOTS-plus) is an effective but costly
strategy for treating multidrug resistant tuberculosis The impact of the implementation of DOTS-plus on overall tuberculosis
control is unknown What this study adds
If DOTS-plus is implemented, it must not divert resources from and
decrease the effectiveness of
DOTS
tsterls{at}jhmi.edu
Design:
Decision analysis with Monte Carlo simulation of a Markov decision tree.
Data sources:
People with smear positive pulmonary tuberculosis.
Data analysis:
Analyses modelled different levels of
programme effectiveness of DOTS and DOTS-plus, and high (10%) and
intermediate (3%) proportions of primary multidrug resistant
tuberculosis, while accounting for exogenous reinfection.
Main outcome measure:
The cumulative number of
tuberculosis deaths per 100 000 population over 10 years.
Results:
The model predicted that under DOTS, 276 people would die from tuberculosis (24 multidrug resistant and 252 not multidrug resistant) over 10 years under optimal implementation in an
area with 3% primary multidrug resistant tuberculosis. Optimal implementation of DOTS-plus would result in four (1.5%) fewer deaths.
If implementation of DOTS-plus were to result in a decrease of just 5%
in the effectiveness of DOTS, 16% more people would die with
tuberculosis than under DOTS alone. In an area with 10% primary
multidrug resistant tuberculosis, 10% fewer deaths would occur under
optimal DOTS-plus than under optimal DOTS, but 16% more deaths would
occur if implementation of DOTS-plus were to result in a 5% decrease
in the effectiveness of DOTS
Conclusions:
Under optimal implementation, fewer
tuberculosis deaths would occur under DOTS-plus than under DOTS. If,
however, implementation of DOTS-plus were associated with even minimal decreases in the effectiveness of treatment, substantially more patients would die than under DOTS.
DOTS is an effective, albeit underused, strategy for treating
tuberculosis
If implementation of DOTS-plus is associated with even minimal
decreases in the effectiveness of DOTS, more patients would die with
tuberculosis under DOTS-plus than under DOTS alone
Read all Rapid Responses